Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(186)
•••
Comment by robertshawon Apr 17, 2018 6:03pm
203 Views
Post# 27900991

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:That's 4 out of 4

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:That's 4 out of 4
enriquesuave wrote: BJ is once again trying to distort the truth and results. All it takes is to mix one truth with falsehoods to Fool people.  We ain't no fools BJ.  If BJ was correct then for example EBIO should of never started a PH3 trial because they only achieved 40% CR at 90 days and 16% at 1 year in their PH2 trial where they were primarily aiming for Efficacy ( not safety).  In our PH1 b where we are aiming at Safety, and meeting it so far, we are already seeing 100% efficacy at 90 days. That to me is extremely encouraging when looking ahead at PH2. Already I believe that we will turn heads when PMH gives final read out at end of PH1.    Give it up man. You look really stupid.  Get another job.  


A fox may turn gray ,but never kind. Basement pimp will never change.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities